The interplay between lung galectins and pro-fibrotic markers in post-COVID-19 fibrogenesis: A pilot study.

Aims: COVID-19, caused by the SARS-CoV-2 virus, can lead to serious lung conditions, notably interstitial pulmonary fibrosis.

Main Methods: Our study tracked the progression of fibrosis markers in serial bronchoalveolar lavage (BAL) measurements collected from 16 COVID-19 patients at 1, 3, and 6 months post-infection. Additionally, BAL samples from 10 healthy control subjects were included.

Space-confined mediation of electron transfer for efficient biomolecular solar conversion.

Solar-converting nanosystems using self-renewing biomaterial resources carry great potential for developing sustainable technologies to ameliorate climate change and minimize reliance on fossil fuels. By mimicking natural photosynthesis, diverse proof-of-concept biosolar systems have been used to produce green electricity, fuels and chemicals. Efforts so far have focused on optimizing light harvesting, biocatalyst loading and electron transfer (ET), however, the long-term performance of best-performing systems remains a major challenge due to the intensive use of diffusive, toxic mediators.

Vitamin D serum levels in patients with systemic sclerosis and very early systemic sclerosis (VEDOSS).

Introduction: Vitamin D may be capable of interfering with the pathophysiological pathways involved in systemic sclerosis, by virtue of its well-known immunomodulatory effects. In this study, we aimed at evaluating the differences and the correlations between vitamin D levels in systemic sclerosis patients versus patients with very early systemic sclerosis.

Methods: One hundred twenty-six patients (80 definite systemic sclerosis and 46 very early systemic sclerosis) were included in this case control study.

The HYdrocortisone for Bronchopulmonary Dysplasia Respiratory and Developmental (HYBRiD) outcomes study: protocol for a longitudinal cohort study.

Background: Bronchopulmonary dysplasia (BPD) affects up to half of extremely preterm infants, and is associated with adverse long-term respiratory, neurodevelopmental, and educational sequelae and costly health service and family economic outcomes. The NICHD Neonatal Research Network Hydrocortisone for Bronchopulmonary Dysplasia (BPD) Trial evaluated the efficacy and safety of hydrocortisone treatment to prevent BPD in high-risk infants. The trial enrolled 800 very preterm infants with respiratory failure and followed the participants until 2 years corrected age to assess safety of the trial intervention.